These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 30407322)
21. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator. Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443 [TBL] [Abstract][Full Text] [Related]
22. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA; Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454 [TBL] [Abstract][Full Text] [Related]
24. Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery. Chic Acevedo C; Velasco F; Herrera C Future Cardiol; 2015 Sep; 11(5):525-9. PubMed ID: 26090568 [TBL] [Abstract][Full Text] [Related]
25. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196 [TBL] [Abstract][Full Text] [Related]
26. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. Sherwood MW; Nessel CC; Hellkamp AS; Mahaffey KW; Piccini JP; Suh EY; Becker RC; Singer DE; Halperin JL; Hankey GJ; Berkowitz SD; Fox KAA; Patel MR J Am Coll Cardiol; 2015 Dec; 66(21):2271-2281. PubMed ID: 26610874 [TBL] [Abstract][Full Text] [Related]
29. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085 [TBL] [Abstract][Full Text] [Related]
30. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. Ishihara H; Torii H; Imoto H; Oka F; Sadahiro H; Suzuki M J Stroke Cerebrovasc Dis; 2014; 23(10):e457-e459. PubMed ID: 25280819 [TBL] [Abstract][Full Text] [Related]
31. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy. Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742 [TBL] [Abstract][Full Text] [Related]
32. Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study. Evans A; Davies M; Osborne V; Roy D; Shakir S PLoS One; 2020; 15(10):e0240489. PubMed ID: 33035259 [TBL] [Abstract][Full Text] [Related]
33. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism. Chojnowski K; Górski T; Robak M; Treliński J Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971 [TBL] [Abstract][Full Text] [Related]
34. Which oral anticoagulant for atrial fibrillation. Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507 [No Abstract] [Full Text] [Related]
35. Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents. Platton S; Bowles L; MacCallum P Br J Haematol; 2017 Nov; 179(3):511-513. PubMed ID: 27392166 [No Abstract] [Full Text] [Related]
36. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding. Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440 [TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma. Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991 [TBL] [Abstract][Full Text] [Related]
38. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers. Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448 [TBL] [Abstract][Full Text] [Related]
39. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG; Camm AJ Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):70-79. PubMed ID: 30423165 [TBL] [Abstract][Full Text] [Related]
40. Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy? Silva VM; Scanavacca M; Darrieux F; Cavalheiro C; Strunz CC Clin Appl Thromb Hemost; 2019; 25():1076029619835053. PubMed ID: 30907118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]